Korea Atomic Energy Research Institute

Sun Ju Choi

Sang Hyun Park

Kyung Bae Park

Byung Chul Shin

Sang Mu Choi

Hui Jeong Gwon

Beom Su Jang

Woong Woo Park

Kwang Hee Han

Young Don Hong

Jae Deok Lim

Seong Ho Choi

Dong Eun Lee

Jin-Hee Lee

Kwang Jae Son

Jin Ho Moon

So-Young Lee

Young-Don Hong

Jong Bum Kim

Sung-Hee Jung

Sang Ei Seo

Sung-Soo Nam

Kang Hyuk Choi

A method of preparing radioisotope hybrid nanocomposite particles using a sol-gel reaction, and radioisotope hybrid nanocomposite particles prepared using the same are provided. The method includes preparing a complex precursor using a metal ion and an unshared electron pair reactive compound, growing hybrid nanocomposite particles based on the complex precursor by means of a sol-gel reaction, calcining the nanocomposite particles in the air to remove organic matters present in the nanocomposite particles, and irradiating the nanocomposite particles with neutrons to prepare radioisotope hybrid nanocomposite particles. The radioisotope nanocomposite particles prepared using the method can be used as diagnostic and therapeutic particles in the fields of oil refining, chemistry, cement, agriculture, water resources, environment, ocean, and medicine, and can also be used as a radioisotope tracer for evaluating the risk of nanomaterials.

Method of preparing radioisotope hybrid nanocomposite particles using sol-gel reaction and radioisotope hybrid nanocomposite particles prepared using the same

The present invention provides a technique for adsorbing I-125 on a support for treating cancer and a method of preparing an I-125 seed using the same. Since a method of preparing iodine according to the present invention uses an intermediate having phosphate-based, oxalate-based, or arsenate-based anions introduced thereinto, the intermediate has a substitution effect of iodine 3 to 5 times higher than that of a typically used intermediate having chlorine anions introduced thereinto. According to the substitution effect, control of a radiation dose may be possible during the manufacturing of an iodine seed and an iodine seed may be prepared within a shorter period of time. Also, since an amount of residual radioactive iodine may be decreased as a result of a large amount of adsorption, an amount of radioactive iodine (I-125) waste may be decreased, and the effect thereof may be also high environmentally.

Method of preparing iodine seed for treating eye disease or cancer, and iodine seed prepared thereby

Novel NSchelator-folate derivatives, a preparation method thereof, and a composition for diagnosis and treatment of tumor including the same as an active ingredient are provided. The novel NSchelator-folate derivatives or a pharmaceutically acceptable salt thereof are easily introduced into the cells using receptor binding to tumor expressing &#x3b1;-folate receptor (&#x3b1;-FR). Accordingly, the folate derivatives, labeled with radioisotope such as technetium, or rhenium, can be advantageously used for the diagnosis and treatment of tumor using tumor imaging and irradiation from the isotope, and therefore, can be widely used for the purpose of labeling a variety of radiopharmaceuticals.

[object Object]

A method for labelling a sulfide compound with technetium or rhenium, comprising the reaction of a disulfide compound with pertechnetate or perrhenate in the presence of borohydride exchange resin to obtain a complex of technetium or rhenium with the sulfide compound. The method can directly label disulfide compounds with technetium or rhenium, can skip the synthetic step of thiol-protected S-precursor, and is useful for high value-added radiopharmaceuticals.

Method for labelling technetium or rhenium using borohydride exchange resin

The present invention relates to a method of preparing technetium or rhenium complex for radiopharmaceuticals, through reaction of pertechnetate or perrhenate with a ligand in the presence of a reducing agent, wherein the reducing agent is a borohydride exchange resin (BER). The borohydride exchange resin of the present invention has advantages of being stable in a wide range of Ph, including acidic or alkaline condition(Ph 2&#x2dc;14) and thus being applicable to biological materials as well as being easily removable through filtration when being administrated. Also since the radiolabelled complex is produced under conditions milder than those required for the conventional reducing agents as well as has high radiochemical purity and high labeling efficiency, the conventional reducing agents can be replaced by the BER of the present invention.

Method for the preparation of technetium or rhenium complex for radiopharmaceuticals

Disclosed is a method of preparing a rhenium complex by use of a borohydride exchange resin, including dissolving perrhenic acid in a solution containing ethylenediamine tetraacetate, mannitol and stannous chloride to obtain a perrhenic acid solution (step 1), which is then mixed with disulfide in the presence of a borohydride exchange resin and reacts at room temperature, to obtain a rhenium complex (step 2). The preparation method of the current invention is characterized in that rhenium is reduced to have a desired oxidation number through the dissolving of the step 1, whereby the reaction of the step 2 can occur at room temperature. In addition, use of the borohydride exchange resin as a reducing agent results in direct formation of the rhenium complex of sulfide from disulfide, without the need of synthesis of thiol-protected S-precursor. Therefore, radioactive pharmaceuticals having high values can be economically and efficiently produced.

Method of preparing rhenium complex using borohydride exchange resin

Growing community of inventors

Daejeon, South Korea

Sun Ju Choi